company background image
MEDS logo

TRxADE HEALTH NasdaqCM:MEDS Stock Report

Last Price

US$6.93

Market Cap

US$8.4m

7D

-12.3%

1Y

51.2%

Updated

18 Apr, 2024

Data

Company Financials

MEDS Stock Overview

TRxADE HEALTH, Inc. operates as a health services IT company in the United States.

MEDS fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health3/6
Dividends0/6

TRxADE HEALTH, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for TRxADE HEALTH
Historical stock prices
Current Share PriceUS$6.93
52 Week HighUS$44.56
52 Week LowUS$3.69
Beta1.93
1 Month Change-66.49%
3 Month Change57.50%
1 Year Change51.23%
3 Year Change-89.80%
5 Year Change-81.22%
Change since IPO-99.99%

Recent News & Updates

Recent updates

TRxADE Health prices of $1.8M stock offering

Oct 05

TRxADE Health launches next day delivery services via Trxade prime plus program

Aug 30

TRxADE Health proposes public stock offering

Aug 23

Trxade Group GAAP EPS of -$0.13 misses by $0.05, revenue of $3.3M beats by $0.37M

Jul 25

Will TRxADE HEALTH (NASDAQ:MEDS) Spend Its Cash Wisely?

Mar 30
Will TRxADE HEALTH (NASDAQ:MEDS) Spend Its Cash Wisely?

Here's Why We're Watching TRxADE HEALTH's (NASDAQ:MEDS) Cash Burn Situation

Nov 23
Here's Why We're Watching TRxADE HEALTH's (NASDAQ:MEDS) Cash Burn Situation

Need To Know: Analysts Just Made A Substantial Cut To Their TRxADE HEALTH, Inc. (NASDAQ:MEDS) Estimates

Jul 29
Need To Know: Analysts Just Made A Substantial Cut To Their TRxADE HEALTH, Inc. (NASDAQ:MEDS) Estimates

Pharma Pain Points - Trxade CEO Suren Ajjarapu (Video)

Jun 16

SpartanNash and Bonum Health join hands to provide telemedicine services

Jun 07

Shareholders Will Probably Hold Off On Increasing Trxade Group, Inc.'s (NASDAQ:MEDS) CEO Compensation For The Time Being

May 22
Shareholders Will Probably Hold Off On Increasing Trxade Group, Inc.'s (NASDAQ:MEDS) CEO Compensation For The Time Being

Earnings Release: Here's Why Analysts Cut Their Trxade Group, Inc. (NASDAQ:MEDS) Price Target To US$10.00

Apr 28
Earnings Release: Here's Why Analysts Cut Their Trxade Group, Inc. (NASDAQ:MEDS) Price Target To US$10.00

Time To Worry? Analysts Just Downgraded Their Trxade Group, Inc. (NASDAQ:MEDS) Outlook

Apr 01
Time To Worry? Analysts Just Downgraded Their Trxade Group, Inc. (NASDAQ:MEDS) Outlook

Did Business Growth Power Trxade Group's (NASDAQ:MEDS) Share Price Gain of 143%?

Feb 05
Did Business Growth Power Trxade Group's (NASDAQ:MEDS) Share Price Gain of 143%?

Shareholder Returns

MEDSUS Healthcare ServicesUS Market
7D-12.3%-6.1%-3.7%
1Y51.2%-11.9%20.2%

Return vs Industry: MEDS exceeded the US Healthcare Services industry which returned -11.5% over the past year.

Return vs Market: MEDS exceeded the US Market which returned 20.5% over the past year.

Price Volatility

Is MEDS's price volatile compared to industry and market?
MEDS volatility
MEDS Average Weekly Movement48.8%
Healthcare Services Industry Average Movement9.9%
Market Average Movement6.0%
10% most volatile stocks in US Market16.6%
10% least volatile stocks in US Market3.0%

Stable Share Price: MEDS's share price has been volatile over the past 3 months.

Volatility Over Time: MEDS's weekly volatility has increased from 33% to 49% over the past year.

About the Company

FoundedEmployeesCEOWebsite
n/a34Suren Ajjarapuwww.trxadehealth.com

TRxADE HEALTH, Inc. operates as a health services IT company in the United States. The company focuses on digitalizing the retail pharmacy experience by optimizing drug procurement, prescription journey, and patient engagement. It operates the TRxADE drug procurement marketplace, which offers price transparency, purchasing capabilities, and other value-added services; and offers patient centric telehealth services under the Bonum Health brand name.

TRxADE HEALTH, Inc. Fundamentals Summary

How do TRxADE HEALTH's earnings and revenue compare to its market cap?
MEDS fundamental statistics
Market capUS$8.35m
Earnings (TTM)-US$3.55m
Revenue (TTM)US$9.37m

0.9x

P/S Ratio

-2.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
MEDS income statement (TTM)
RevenueUS$9.37m
Cost of RevenueUS$3.95m
Gross ProfitUS$5.42m
Other ExpensesUS$8.97m
Earnings-US$3.55m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-2.95
Gross Margin57.82%
Net Profit Margin-37.90%
Debt/Equity Ratio45.5%

How did MEDS perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.